-
Article
Open AccessCorrection: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design
-
Article
Open AccessDaratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience
-
Article
Open Access“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience
Belantamab mafodotin is a highly selective targeted therapy for multiple myeloma. It targets the B cell maturation antigen (BCMA) on plasma cells and showed promising results in several randomized clinical tri...
-
Article
Open AccessOutcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design
-
Article
Open AccessSerum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
Soluble BCMA (sBCMA) levels are elevated in monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). However, the association between sBCMA levels and prognosis in MGUS ...
-
Article
N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression
Our group previously demonstrated that M-protein light chain (LC) glycosylation can be detected on routine MASS-FIX testing. Glycosylation is increased in patients with immunoglobulin LC amyloidosis (AL) and r...
-
Article
Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains
Hematologic response criteria in light chain (AL) amyloidosis require the difference in involved and uninvolved free light chains (dFLC) to be at least 5 mg/dl. We describe the clinical presentation and outcom...
-
Article
Pomalidomide–dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial
Despite therapeutic advances, multiple myeloma remains incurable, with limited options for patients with refractory disease. We conducted a large, multi-cohort clinical trial testing various doses and treatmen...
-
Article
Natural history of t(11;14) multiple myeloma
Translocation (11;14) on interphase fluorescent in situ hybridization in plasma cells is regarded as a standard risk prognostic marker in multiple myeloma based on studies conducted before introduction of current...
-
Article
Open AccessPrevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10–49 years old: a population-based study from the National Health and Nutrition Examination Survey
We studied the prevalence of monoclonal gammopathy of undetermined significance (MGUS) in younger individuals, age 10–49 years, using samples from the National Health and Nutritional Examination Survey (NHANES...
-
Article
Open AccessPrognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma
Fluorescence in situ hybridization evaluation is essential for initial risk stratification in multiple myeloma. While the presence of specific cytogenetic high-risk abnormalities (HRA) is known to confer a poor p...
-
Article
Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category
The significance of interphase fluorescence in situ hybridization (iFISH) by regimen type was assessed in 692 immunoglobulin light-chain (AL) amyloidosis patients with iFISH at diagnosis. First-line treatment was...
-
Article
Open AccessChanges in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma
Little is known about the impact of multiple myeloma (MM) treatment on uninvolved immunoglobulins (Ig). We identified 448 patients who received high-dose dexamethasone (HD-DEX), lenalidomide and dexamethasone ...
-
Article
Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression
The presence of high numbers of circulating clonal plasma cells (cPCs) in patients with smoldering multiple myeloma (SMM), detected by a slide-based immunofluorescence assay, has been associated with a shorter...
-
Article
Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival
Immunoparesis is an adverse prognostic marker in plasma cell proliferative disorders. Its impact in AL amyloidosis has not been explored in depth. Newly diagnosed AL amyloidosis patients (n=998) were evaluated fo...
-
Article
Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents
Outcomes for patients with multiple myeloma (MM) have improved in recent years owing to use of novel agents and high-dose therapy followed by autologous stem cell transplant (ASCT). We analyzed the outcomes of...
-
Article
Open AccessPrevalence, incidence and survival of smoldering multiple myeloma in the United States
-
Article
Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy
-
Article
Open AccessEvolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma
We studied 190 patients with smoldering multiple myeloma (SMM) at our institution between 1973 and 2014. Evolving change in monoclonal protein level (eMP) was defined as ⩾10% increase in serum monoclonal prote...
-
Article
Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment
Although clinical improvement is almost universal with therapy in patients with POEMS (an acronym for polyneuropathy, organomegaly, endocrinopathies, monoclonal protein and a variety of skin changes) syndrome,...
